RegeneRx Biopharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc.
Your view on RGRX
Overview
What the company does, where it operates, and who runs it.
About RegeneRx Biopharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- J. J. Finkelstein
- Headquarters
- 15245 Shady Grove Road, Rockville, MD, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- J. J. Finkelstein
- Headquarters
- 15245 Shady Grove Road, Rockville, MD, US
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration.
The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.
It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for RegeneRx Biopharmaceuticals, Inc. from FRC's valuation model, read against the market price. RGRX last traded at $0.0003; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for RegeneRx Biopharmaceuticals, Inc.. Starting points for RegeneRx Biopharmaceuticals, Inc.: EPS -$0.01, beta 4.73 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for RegeneRx Biopharmaceuticals, Inc.. RegeneRx Biopharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for RegeneRx Biopharmaceuticals, Inc.. Trailing twelve-month EPS for RegeneRx Biopharmaceuticals, Inc. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Analyst Ratings
- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2017 |
|---|---|
| Avg. estimate | $0.00 |
| Low estimate | $0.00 |
| High estimate | $0.00 |
| No. of analysts | 0 |
| Year-ago EPS | — |
| Growth | — |
Revenue Estimate
| Revenue | Current QtrDec 2017 |
|---|---|
| Avg. estimate | $13500.00 |
| Low estimate | $10000.00 |
| High estimate | $17000.00 |
| No. of analysts | 1 |
| Year-ago revenue | — |
| Growth | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for RegeneRx Biopharmaceuticals, Inc.. RegeneRx Biopharmaceuticals, Inc. has reported as a listed company since 2003. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- CHNXFChitogenX Inc.Biotechnology$627,628
- DRWNQuantum Medical Transport, Inc.Medical - Care Facilities$23,978
- FFNTF4Front Ventures Corp.Drug Manufacturers - Specialty & Generic$62,300
- FORZForza Innovations Inc.Medical - Devices$252,183
- HMGNHemagen Diagnostics, Inc.Biotechnology$3,100
- NBIONascent Biotech, Inc.Biotechnology$51,665
More Biotechnology companies
- ORGSOrgenesis Inc.OTC$3M
- ORICORIC Pharmaceuticals, Inc.NASDAQ$795M
- ORKAOruka Therapeutics, Inc.NASDAQ$6.5B
- ORMPOramed Pharmaceuticals Inc.NASDAQ$169M
- ORPOFOSE Immunotherapeutics S.A.OTC$260M
- ORYZFOryzon Genomics S.A.OTC$284M
- OSRHWOSR Holdings, Inc.NASDAQ$8M
- OSTXOS Therapies IncorporatedAMEX$48M
- OTLCOncotelic Therapeutics, Inc.OTC$21M
- OTLKOutlook Therapeutics, Inc.NASDAQ$99M
- OVIDOvid Therapeutics Inc.NASDAQ$427M
- OXBOFOxford BioDynamics PlcOTC$4M
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by RegeneRx Biopharmaceuticals, Inc. executives and directors. Shares of RegeneRx Biopharmaceuticals, Inc. have traded between $0.0002 and $0.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for RegeneRx Biopharmaceuticals, Inc.. Coverage tracks RegeneRx Biopharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of RegeneRx Biopharmaceuticals, Inc.